Login to Your Account

In The Clinic NEWS

Supernus Pharmaceuticals Inc. shares fell 23.4 percent Tuesday after the company dropped one of two doses of an experimental treatment for impulsive aggression in children with ADHD that it was evaluating in twin phase III studies.

A pivotal trial comparing lefamulin, Nabriva Therapeutics plc's antibiotic for patients with CABP, to the standard-of-care treatment, moxifloxacin, found it noninferior to the well-known quinolone.

DUBLIN – Bavarian Nordic A/S lost half its market value Friday when an interim analysis showed that a phase III trial of its cancer vaccine, Prostvac, was not going to deliver a good result.

More In The Clinic Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: